Liposomal vaccine delivery systems

Malou Henriksen-Lacey, Karen Smith Korsholm, Peter Andersen, Yvonne Perrie, Dennis Christensen

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Liposomes remain at the forefront of drug and vaccine design owing to their well-documented abilities to act as delivery vehicles. Nevertheless, the concept of liposomes as delivery vehicles is not a new one, with most works focusing on their use for the delivery of genes and drugs. However, in the last 10 years a significant amount of research has focused on using liposomes as vaccine adjuvants, not only as an antigen delivery vehicle but also as a tool to increase the immunogenicity of peptide and protein antigens. AREAS COVERED: This paper reviews liposomal adjuvants now in vaccine development, with particular emphasis on their adjuvant mechanism and how specific physicochemical characteristics of liposomes affect the immune response. The inclusion of immunomodulators is also discussed, with prominence given to Toll-like receptor ligands. EXPERT OPINION: The use of liposomes as vaccine delivery systems is evolving rapidly owing to the combined increase in technological advances and understanding of the immune system. Liposomes that contain and deliver immunostimulators and antigens are now being developed to target diseases that require stimulation of both humoral and cell-mediated immune responses. The CAF liposomal system, described in detail in this review, is one liposomal model that shows such flexibility.
LanguageEnglish
Pages505-519
Number of pages15
JournalExpert Opinion on Drug Delivery
Volume8
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Liposomes
Vaccines
Antigens
Toll-Like Receptors
Drug Design
Immunologic Factors
Immune System
Ligands
Peptides
Research
Pharmaceutical Preparations
Genes
Proteins

Keywords

  • immunologic adjuvants
  • animals
  • antigens
  • drug delivery systems
  • drug design
  • humans
  • ligands
  • liposomes
  • surface properties
  • toll-like receptors
  • vaccines

Cite this

Henriksen-Lacey, M., Korsholm, K. S., Andersen, P., Perrie, Y., & Christensen, D. (2011). Liposomal vaccine delivery systems. Expert Opinion on Drug Delivery, 8(4), 505-519. https://doi.org/10.1517/17425247.2011.558081
Henriksen-Lacey, Malou ; Korsholm, Karen Smith ; Andersen, Peter ; Perrie, Yvonne ; Christensen, Dennis. / Liposomal vaccine delivery systems. In: Expert Opinion on Drug Delivery. 2011 ; Vol. 8, No. 4. pp. 505-519.
@article{7b83ed8998264a3daf3502265ea095ac,
title = "Liposomal vaccine delivery systems",
abstract = "INTRODUCTION: Liposomes remain at the forefront of drug and vaccine design owing to their well-documented abilities to act as delivery vehicles. Nevertheless, the concept of liposomes as delivery vehicles is not a new one, with most works focusing on their use for the delivery of genes and drugs. However, in the last 10 years a significant amount of research has focused on using liposomes as vaccine adjuvants, not only as an antigen delivery vehicle but also as a tool to increase the immunogenicity of peptide and protein antigens. AREAS COVERED: This paper reviews liposomal adjuvants now in vaccine development, with particular emphasis on their adjuvant mechanism and how specific physicochemical characteristics of liposomes affect the immune response. The inclusion of immunomodulators is also discussed, with prominence given to Toll-like receptor ligands. EXPERT OPINION: The use of liposomes as vaccine delivery systems is evolving rapidly owing to the combined increase in technological advances and understanding of the immune system. Liposomes that contain and deliver immunostimulators and antigens are now being developed to target diseases that require stimulation of both humoral and cell-mediated immune responses. The CAF liposomal system, described in detail in this review, is one liposomal model that shows such flexibility.",
keywords = "immunologic adjuvants, animals, antigens, drug delivery systems, drug design, humans, ligands, liposomes, surface properties, toll-like receptors, vaccines",
author = "Malou Henriksen-Lacey and Korsholm, {Karen Smith} and Peter Andersen and Yvonne Perrie and Dennis Christensen",
year = "2011",
month = "4",
doi = "10.1517/17425247.2011.558081",
language = "English",
volume = "8",
pages = "505--519",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "4",

}

Henriksen-Lacey, M, Korsholm, KS, Andersen, P, Perrie, Y & Christensen, D 2011, 'Liposomal vaccine delivery systems' Expert Opinion on Drug Delivery, vol. 8, no. 4, pp. 505-519. https://doi.org/10.1517/17425247.2011.558081

Liposomal vaccine delivery systems. / Henriksen-Lacey, Malou; Korsholm, Karen Smith; Andersen, Peter; Perrie, Yvonne; Christensen, Dennis.

In: Expert Opinion on Drug Delivery, Vol. 8, No. 4, 04.2011, p. 505-519.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Liposomal vaccine delivery systems

AU - Henriksen-Lacey, Malou

AU - Korsholm, Karen Smith

AU - Andersen, Peter

AU - Perrie, Yvonne

AU - Christensen, Dennis

PY - 2011/4

Y1 - 2011/4

N2 - INTRODUCTION: Liposomes remain at the forefront of drug and vaccine design owing to their well-documented abilities to act as delivery vehicles. Nevertheless, the concept of liposomes as delivery vehicles is not a new one, with most works focusing on their use for the delivery of genes and drugs. However, in the last 10 years a significant amount of research has focused on using liposomes as vaccine adjuvants, not only as an antigen delivery vehicle but also as a tool to increase the immunogenicity of peptide and protein antigens. AREAS COVERED: This paper reviews liposomal adjuvants now in vaccine development, with particular emphasis on their adjuvant mechanism and how specific physicochemical characteristics of liposomes affect the immune response. The inclusion of immunomodulators is also discussed, with prominence given to Toll-like receptor ligands. EXPERT OPINION: The use of liposomes as vaccine delivery systems is evolving rapidly owing to the combined increase in technological advances and understanding of the immune system. Liposomes that contain and deliver immunostimulators and antigens are now being developed to target diseases that require stimulation of both humoral and cell-mediated immune responses. The CAF liposomal system, described in detail in this review, is one liposomal model that shows such flexibility.

AB - INTRODUCTION: Liposomes remain at the forefront of drug and vaccine design owing to their well-documented abilities to act as delivery vehicles. Nevertheless, the concept of liposomes as delivery vehicles is not a new one, with most works focusing on their use for the delivery of genes and drugs. However, in the last 10 years a significant amount of research has focused on using liposomes as vaccine adjuvants, not only as an antigen delivery vehicle but also as a tool to increase the immunogenicity of peptide and protein antigens. AREAS COVERED: This paper reviews liposomal adjuvants now in vaccine development, with particular emphasis on their adjuvant mechanism and how specific physicochemical characteristics of liposomes affect the immune response. The inclusion of immunomodulators is also discussed, with prominence given to Toll-like receptor ligands. EXPERT OPINION: The use of liposomes as vaccine delivery systems is evolving rapidly owing to the combined increase in technological advances and understanding of the immune system. Liposomes that contain and deliver immunostimulators and antigens are now being developed to target diseases that require stimulation of both humoral and cell-mediated immune responses. The CAF liposomal system, described in detail in this review, is one liposomal model that shows such flexibility.

KW - immunologic adjuvants

KW - animals

KW - antigens

KW - drug delivery systems

KW - drug design

KW - humans

KW - ligands

KW - liposomes

KW - surface properties

KW - toll-like receptors

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=79952949007&partnerID=8YFLogxK

UR - http://informahealthcare.com/doi/abs/10.1517/17425247.2011.558081

U2 - 10.1517/17425247.2011.558081

DO - 10.1517/17425247.2011.558081

M3 - Article

VL - 8

SP - 505

EP - 519

JO - Expert Opinion on Drug Delivery

T2 - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 4

ER -

Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opinion on Drug Delivery. 2011 Apr;8(4):505-519. https://doi.org/10.1517/17425247.2011.558081